FDA Commissioner Marty Makary, MD, MPH, is seeking to drastically cut drug reviews favored by President Donald Trump's administration. [original] This new fast-track FDA program is causing alarm at the agency. [original] The plan may run into legal questions. [original] The article did not provide other specific details about the program or statistics. [original]